Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 2/2005

01-02-2005 | Original Research Article

The impact of anaemia and its treatment on employee disability and medical costs

Authors: Dr Ernst Berndt, William Crown, Joel Kallich, Stacey Long, Xue Song, Gary H. Lyman

Published in: PharmacoEconomics | Issue 2/2005

Login to get access

Abstract

Objective: Anaemia is a common haematological complication of cancer and cytotoxic treatment. The incremental economic burden associated with medical care and short-term disability of anaemia in patients with malignancy and receiving chemotherapy has not been well documented. This study evaluates the effect of anaemia on the costs associated with cancer treated with chemotherapy.
Methods: Patients receiving chemotherapy within 6 months of their initial cancer diagnosis were identified in a commercial claims database for 1999–2000. Data for these individuals were linked to their employers’ short-term disability records via unique encrypted personal identification numbers provided by employers. Patients with anaemia were identified by a diagnosis of anaemia or treatment with transfusion or erythropoietin alfa (EPO). Healthcare expenditure and short-term disability leave were observed for up to 6 months following initial cancer diagnosis and were summarised into monthly averages. Exponential conditional mean models and zero-inflated negative binomial models were used to analyse mean monthly healthcare expenditures and short-term disability days.
Results: Twenty-five percent of the 619 newly diagnosed cancer patients treated with chemotherapy had anaemia. The presence of anaemia and longer length of transfusion therapy were associated with increased expenditures, while longer length of EPO treatment was associated with lower expenditures. The incremental costs due to anaemia among patients receiving chemotherapy were $US5538 (year 2001 values) per month in the first 6 months following cancer diagnosis, 10.8% of which were costs related to short-term disability leave.
Conclusion: Anaemia in patients undergoing chemotherapy presents a substantial burden to employers and payers. The findings also suggest that patients with anaemia treated with erythropoietin alfa can achieve expenditure levels similar to those patients without anaemia.
Literature
1.
Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001; 28 (2 Suppl. 8): 1–6PubMedCrossRef
2.
Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Nall Cancer Inst 1999; 91: 1616–34CrossRef
3.
Ziegler J. When cancer comes to work. Business and Health 1998; 16 (7): 34–7
4.
Carelle N, Piotto E, Bellanger A, et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002; 95: 155–63PubMedCrossRef
5.
Berndt E, Kallich J, McDermot A et al. Reductions in anaemia and fatigue are associated with improvements in productivity. Pharmacoeconomics. In press.
6.
Broadhead WE, Blazer DG, George LK, et al. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990; 264: 2524–8PubMedCrossRef
7.
Comstock GW, Stone RW, Tonascia JA, et al. Respiratory survey findings as predictors of disability from respiratory diseases. Am Rev Respir Dis 1981; 124 (4): 367–71PubMed
8.
Crystal-Peters J, Crown WH, Goetzel RZ, et al. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000; 6: 373–8PubMed
9.
Persson U. The indirect costs of morbidity in type II diabetic patients. Pharmacoeconomics 1995; 8 Suppl. 1: 28–32PubMedCrossRef
10.
Guo HR, Tanaka S, Halperin WE, et al. Back pain prevalence in US industry and estimates of lost workdays. Am J Public Health 1999; 89 (7): 1029–35PubMedCrossRef
11.
Rapoport AM, Adelman JU. Cost of migraine management: a pharmacoeconomic overview. Am J Manag Care 1998; 4 (4): 531–45PubMed
12.
Michel P, Dartigues IF, Duru G, et al. Incremental absenteeism due to headaches in migraine: results from the Mig-Access French national cohort. Cephalalgia 1999; 19 (5): 503–10PubMedCrossRef
13.
Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 1999: 813–8CrossRef
14.
Oxterhaus IT, Gutterman DL, Plachetka JR. Healthcare resource and lost labor costs of migraine headache in the US. Pharmacoeconomics 1992; 2 (1): 67–76CrossRef
15.
Cremieux PY, Slavin MB, Fendrick M, et al. The costs of cancer: cancer-related conditions can add dramatically to overall costs of care. J Manag Care Med 2002; 6 (1): 12–9
16.
D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49: 1429–33PubMedCrossRef
17.
Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the `top 10’ physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med 2003; 45: 5–14PubMedCrossRef
18.
Pauly MV, Nicholson S, Xu J, et al. A general model of the impact of absenteeism on employers and employees. Health Econ 2002; 11: 221–31PubMedCrossRef
19.
Manning WG, Newhouse JP, Duan N, et al. Health insurance and the demand for medical care: evidence from a randomized experiment. Am Econ Rev 1987; 77: 251–77PubMed
20.
Duan N, Manning W, Morris C, et al. A comparison of alternative models for the demand for medical care. KIES 1983; 2 (1): 115–26
21.
Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 1983; 78: 605–10CrossRef
22.
Cameron AC, Trivedi PK. Regression analysis of count data. New York: Cambridge University Press, 1998CrossRef
23.
Barnett A, Cremieux PY, Fendrick AM, et al. Anemia-related costs for cancer patients. J Manag Care Med 2002; 6 (1): 20–8
24.
Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317–9PubMedCrossRef
25.
Varmus H. Disease-specific estimates of direct and indirect costs of illness and NIH support. Bethesda (MD): US Department of Health and Human Services, National Institutes of Health, 1997 Sep
Metadata
Title
The impact of anaemia and its treatment on employee disability and medical costs
Authors
Dr Ernst Berndt
William Crown
Joel Kallich
Stacey Long
Xue Song
Gary H. Lyman
Publication date
01-02-2005
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 2/2005
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200523020-00009

Other articles of this Issue 2/2005

PharmacoEconomics 2/2005 Go to the issue

Leading Article

The diffusion of health economics knowledge in Europe

Original Research Article

Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome

Editorial

Friction-cost method as an alternative to the human-capital approach in calculating indirect costs

Original Research Article

Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder

Original Research Article

Providing systematic guidance in pharmacoeconomic guidelines for analysing costs

Leading Article

The case for stratified cost-effectiveness analysis by baseline health-related QOL